Member LoginDividend CushionValue Trap |
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Jan 25, 2017
Crisis In Wall Street Stock Research; The Solution? Independent Investment Research
Image Source: Sam Valadi. The dot-com bubble showed how conflicts of interests can sometimes “muddy” the waters when it comes to getting a fair and unbiased opinion on a stock from a Wall Street analyst. Today, a new conflict of interest is brewing. The Wall Street Journal recently reported that sometimes “analysts say ‘buy’ to win special access for their clients” with top executives. Bloomberg followed up the Journal’s article with one of its own. Let’s examine what’s going on. Jan 24, 2017
Alibaba Group: Still the Quintessential “Play” on China?
Image Shown: Alibaba’s strong free cash flow generation; source: Alibaba. Alibaba has taken a lot of heat from other publishers, but we’ve long liked the company even if it may no longer be a part of the Best Ideas Newsletter portfolio. Some balk at its valuation, but the company’s free cash flow generation and strong balance-sheet net cash position offer substantial legitimacy and support to shares. Jan 24, 2017
Verizon’s Debt Load Is Too Much and Its Deal with Yahoo Is a Silly Distraction
Image Source: Mike Mozart. Verizon’s financial metrics didn’t stack up during 2016, and management suggested 2017 will be more of the same. We’re cautious on this overleveraged, capital-intensive telecom giant. Jan 24, 2017
J&J Boasts Below-Market Earnings Multiple; Deal with Actelion Not Concerning
Image Shown: J&J’s robust pharma pipeline; source: J&J.There’s a lot to like about J&J’s investment opportunity, not the least of which is its strong pharmaceutical pipeline. Deal-making could challenge its pristine balance sheet, but we don’t expect much to derail our thesis. Jan 24, 2017
McDonald’s: Buyback-Driven Earnings Growth and Faltering US Comps
McDonald’s shares continue to plow ahead as if nothing is wrong. Consolidated sales fell, net earnings dropped, US comps faltered, and all of the company’s EPS performance was buyback driven during the fourth quarter, results released January 23. The company is trading at 22 times trailing earnings and holds a sizable net debt position. Jan 23, 2017
Have Bristol-Myers Squibb’s Shares Finally Found Support?
Image Source: kennijima. Bristol-Myers Squibb has seen its shares fall to $50 from nearly $80 in just the past few months as clinical outcomes of its crucial product Opdivo have come under fire. Have shares finally found support? Let’s have a look. Jan 19, 2017
Fair Value Estimate Changes: Facebook, Twitter, Caterpillar and More...
Let's have a look at the reasons behind several of the recent fair value changes we've made on companies across our coverage universe as of late. Jan 15, 2017
The Coming “Goldman Sachs Era”
Image Source: Jussi. Valuentum covers recent developments in the financials sector, including hopes for a relaxation of certain prohibitive Dodd-Frank rules that, if repealed, could pave the way for improved economic returns across the banking sector during the Trump administration. A look back at the month of September 2008, and how Goldman Sachs may very well shape the financial markets during the next few years are two other areas in the piece. Financials stocks have come roaring back since Trump was elected the 45th President of the United States. We've participated. Jan 11, 2017
MLPs: Williams’ Double Equity Raise
Image Source: Roy Luck. Yet another MLP has elected to simplify its corporate structure. Jan 6, 2017
Department Stores Limp Across Finish Line In 2016
2016 was an abysmal year for major department and general merchandise stores, and the holiday season offered little relief. 2017 may very well not be any different for the group.
prev12345678910111213141516171819202122232425
26272829303132333435363738394041424344454647484950 51525354555657585960616263646566676869707172737475 767778798081828384858687888990919293949596979899100 101102103104105106107108109110111112113114115116117118119120 121122123124125126127128129130131132133134135136137138139140 141142143144145146147148149150151152153154155156157158159160 161162163164165166167168169170171172173174175176177178179180 181182183184185186187188189190191192193194195196197198199200 201202203204205206207208209210211212213214215216217218219220 221222223224225226227228229230231232233234235236237238239240 241242243244245246247248249250251252253254255256257258259260 261262263264265266267268269270271272273274275276277278279280 281282283next The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|